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Abstract
Introduction—Epithelial-mesenchymal transition (EMT) is a process whereby epithelial cells 
assume mesenchymal characteristics to facilitate cancer metastasis. However, EMT also 
contributes to the initiation and development of primary tumors. Prior studies that explored the 
hypothesis that EMT gene variants contribute to EOC risk have been based on small sample sizes 
and none have sought replication in an independent population.
Methods—We screened 1254 SNPs in 296 genes in a discovery phase using data from a 
genome-wide association study of EOC among women of European ancestry (1,947 cases and 
2,009 controls) and identified 793 variants in 278 EMT-related genes that were nominally 
(p<0.05) associated with invasive EOC. These SNPs were then genotyped in a larger study of 
14,525 invasive-cancer patients and 23,447 controls. A p-value <0.05 and a false discovery rate 
(FDR) <0.2 was considered statistically significant.
Results—In the larger dataset, GPC6/GPC5 rs17702471 was associated with the endometrioid 
subtype among Caucasians (OR=1.16, 95%CI=1.07–1.25, p=0.0003, FDR=0.19), while F8 
rs7053448 (OR=1.69, 95%CI=1.27–2.24, p=0.0003, FDR=0.12), F8 rs7058826 (OR=1.69, 
95%CI=1.27–2.24, p=0.0003, FDR=0.12), and CAPN13 rs1983383 (OR=0.79, 95%CI=0.69–0.90, 
p=0.0005, FDR=0.12) were associated with combined invasive EOC among Asians. In silico 
functional analyses revealed that GPC6/GPC5 rs17702471 coincided with DNA regulatory 
elements.
Conclusion—These results suggest that EMT gene variants do not appear to play a significant 
role in the susceptibility to EOC.
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INTRODUCTION
Epithelial ovarian carcinoma (EOC) is the leading cause of gynecological cancer-related 
mortality in the western world. In the United States, 22,000 cases and 14,300 deaths are 
estimated in 2014 (American Cancer Society 2014). A family history of the disease is 
associated with a 2–3 fold increased risk of developing the disease (Auranen et al. 1996), 
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implicating inherited genetic factors (Lichtenstein et al. 2000, Stratton et al. 1998). Germline 
mutations in highly penetrant genes such as BRCA1 and BRCA2 are estimated to account for 
about 40% of the excess familial risk (Narod and Foulkes 2004). Given little evidence for 
additional highly penetrant genes, the prevailing consensus is that the remaining familial risk 
reflects common susceptibility alleles that confer low risk. Indeed, genome-wide association 
studies (GWAS) and large-scale replication studies have identified some common 
susceptibility alleles that collectively account for another 4% of the excess familial risk 
(Pharoah et al. 2013). Thus, more variants remain to be identified.
Epithelial-mesenchymal transition (EMT) is a fundamental embryonic process whereby 
epithelial cells assume mesenchymal characteristics to facilitate migration through the 
extracellular matrix (ECM) into the interior of the embryo to contribute to the development 
of internal organs (Davidson, Trope and Reich 2012, Nieto 2013, Thiery et al. 2009). EMT 
is a complex process, accompanied by changes in the expression of multiple and diverse 
factors, including cell adhesion molecules, growth factors, metalloproteinases, transcription 
factors and epithelial markers (Thiery et al. 2009). A role for EMT in cancer has mostly 
been limited to cancer cell invasion and metastatic spread, where malignant cells lose their 
epithelial characteristics and assume mesenchymal properties that promote ECM invasion 
and metastasis (Thiery et al. 2009). However, several lines of evidence support the 
hypothesis that EMT contributes to the initiation and development of primary tumors: (i) the 
expression of inducers of EMT in non-invasive neoplastic lesions, (ii) drivers of EMT 
attenuate key tumor suppressive mechanisms in epithelial cells by affecting the functions of 
modulators of p53 and retinoblastoma dependent pathway, and (iii) the involvement of EMT 
in cell differentiation and tissue homeostasis (Nieto 2013, Puisieux, Brabletz and Caramel 
2014). It is plausible that variants in EMT genes may alter gene expression and therefore 
contribute to inter-individual variation in the risk of ovarian cancer.
Previous studies of variants in EMT-related genes, such as vascular endothelial growth 
factor (VEGF) (Polterauer et al. 2007, Schultheis et al. 2008, Goode et al. 2010, Steffensen 
et al. 2010), matrix-metalloprotease genes (MMPs) (Schildkraut et al. 2009b), TP53 
(Schildkraut et al. 2009a, Galic et al. 2007), E-cadherin (Li et al. 2008), nitric oxide synthase 
(NOS) (Hefler et al. 2002), heparanase (HPN) (Ralph et al. 2007) and PIK3CA (Quaye et al. 
2009, Quaye et al. 2008) provide support for the hypothesis. However, the majority of the 
studies were based on small sample sizes with no replications. Furthermore, variation in 
association by histological subtype and race was not established. In this study, we selected 
793 SNPs from 278 EMT-related genes based on nominal associations with EOC in a 
genome-wide association study among women of European ancestry and performed a 
replication study involving 14,525 case subjects with invasive disease and 23,447 controls 
from 43 sites in the Ovarian Cancer Association Consortium (OCAC), as part of the 
Collaborative Oncological Gene-environment Study (COGS). This large sample size of the 
replication study also provided an opportunity to explore associations by histological 
subtypes of EOC and by race.
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MATERIALS AND METHODS
Discovery set
We initially selected SNPs based on screening of the results from the North American 
genome-wide association study (GWAS). Details of this study have been published 
elsewhere (Permuth-Wey et al. 2011). Briefly, five case-control studies contributed a total of 
1,947 EOC cases and 2,009 controls (of European ancestry) to the North American GWAS. 
Genotyping for four of the studies was performed using the Illumina 610-quad Beadchip 
Array, while the fifth study was genotyped using the Illumna 317K and 370K arrays. 
Additional markers were imputed to account for non-overlapping markers in the two 
genotyping efforts and to improve genome coverage. A total of 2,508,744 (including the 
1254 EMT-related SNPs) out of 2,543,887 SNPs (98.6%) passed quality control.
Collaborative Oncological Gene-environment Study
SNPs that were nominally (P<0.05) associated with ovarian cancer in the discovery set were 
genotyped in the Collaborative Oncological Gene-environment Study (COGS) that included 
43 individual studies from OCAC. Details of this study have been published elsewhere 
(Pharoah et al. 2013). Briefly, 34 case-control studies contributed 14,525 EOC cases and 
23,447 controls of white-European ancestry, 150 cases and 200 controls of African ancestry, 
and 714 cases and 1574 controls of Asian ancestry. Ancestry was assigned using Local 
Ancestry in adMixed Populations (Sankararaman, 2008) based on genotype frequency for 
intercontinental ancestry. Participants with >90% white-European ancestry were defined as 
European and those with >80% African or Asian ancestry were defined as African or Asian, 
respectively. Population substructure within each ancestry group was determined by 
principal components analyses using a set of 37,000 uncorrelated markers. The first five 
principal components were employed for analyses of Europeans and Asians and the first one 
for Africans. The COGS dataset was used to perform SNP-specific analyses for each of the 
four main histological subtypes (serous, endometroid, clear cell and mucinous), and each 
race.
Independent Replication set
The COGS dataset included 62% (1,207 cases and 1,246 controls) of the samples from 
women of white-European ancestry that were genotyped in the discovery set. Therefore we 
excluded all these samples from the COGS dataset to create an independent replication set. 
This independent replication set was used to replicate SNPs identified for all invasive EOC 
among women of European ancestry in the discovery dataset.
SNP selection, genotyping and quality control
EMT-related genes were identified through review of the published literature 
(www.pubmed.gov) and pathways described in the Cancer Genome Anatomy Project. 
Genotype data from HapMap, Perlegen and the NIEHS resequencing projects were then 
used to select tagSNPs (r2 > 0.8), non-synonymous coding SNPs and putative functional 
SNPs from unrelated Caucasian samples. A total of 15,816 SNPs in 296 EMT genes had 
results available in the discovery dataset. The final selection of EMT-related SNPs for 
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genotyping in the large COGS dataset was informed by data from the discovery set and 
design scores from Illumina as previously described (6). SNPs were ranked based on P-
value in the discovery set and the 793 SNPs associated with risk of combined invasive EOC 
or serous ovarian cancer at a nominal P < 0.05 were selected (Supplementary Table 1). All 
793 SNPs were successfully designed for genotyping and included as part of the “candidate 
SNPs” on the custom Illumina Infinium iSelect array that had a total of 211,155 SNPs 
designed for COGS (Pharoah et al. 2013).
Genotyping was performed using an Illumina Infinium iSelect BeadChip at McGill 
University-Génome Québec Innovation Centre and the Mayo Clinic Medical Genome 
Facility following established quality control criteria (Pharoah et al. 2013). The concordance 
for 1,251 duplicate samples was 99.6%. Out of the 211,155 SNPs included on the array, 
94.5% passed quality control (QC). All 793 SNPs in the present study were genotyped 
successfully and passed QC.
In silico analysis using publicly available datasets
We used publicly available data to test for evidence of functional effects of the SNPs using 
Haploreg (http://www.broadinstitute.org/mammals/haploreg/haploreg.php), ENCODE 
(http://genome.ucsc.edu/ENCODE/) and ovary super-enhancer datasets (Ward & Kellis 
2012, Hnisz et al. 2013). These datasets were used to identify epigenetic marks coinciding 
with risk associated SNPs.
Functional Analyses
An in vitro model of early-stage ovarian cancer has been previously described (Lawrenson 
et al. 2011). Briefly, Illumina HT12 gene expression microarrays were used to profile the 
transcriptome of 3D models of normal ovarian cells immortalized with TERT and 
overexpressing cMYC and a mutant KRAS or BRAF allele.
Statistical methods
Participants’ demographic and clinical characteristics by cancer status were compared using 
t-tests for continuous variables and chi-square tests for categorical variables. Statistical 
analysis methods for the discovery dataset have been described previously (Permuth-Wey et 
al. 2011). Analyses of the independent replication set and the COGS dataset were performed 
as follows. Associations between each SNP and case-control status were estimated as log-
linear per allele odds ratios (ORs) with associated 95% confidence intervals (95% CIs) using 
unconditional logistic regression that treated the number of alleles of interest as ordinal 
variables. The ORs specific for each histological subtype was estimated by comparing cases 
of that subtype to all available controls as reference.
All models included variables for study site and for the first five (for Europeans and Asians) 
or one (for Africans) ancestry-specific principal components as covariates. False discovery 
rates (FDR) were calculated to control for multiple testing. Statistical tests were two-sided 
with an alpha level < 0.05 and an FDR < 0.2 considered statistically significant. All 
statistical analyses were implemented with SAS/Genetics version 9.2 (SAS Institute, NC).
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RESULTS
A detailed description of the OCAC studies and study participants in the discovery 
(Permuth-Wey et al. 2011) and COGS (Pharoah et al. 2013) datasets are provided elsewhere. 
In the large COGS dataset, the majority of women (93.5%, n=37,972) were of European 
ancestry; only 0.9% (n=350) and 5.6% (n=2288) were of African or Asian ancestry, 
respectively (Table 1). As expected, the proportion of serous histological subtype was higher 
than the proportions for other subtypes for all race groups.
In the first step, we screened 15,816 SNPs in 296 EMT-related candidate genes in the 
GWAS data set, which consisted of women of European ancestry only. A total of 793 SNPs 
in 278 genes were nominally (p<0.05) associated with the risk of all invasive EOC. Seven of 
the 793 SNPs showed a nominal consistent (in direction) association with risk of invasive 
EOC among women of European ancestry in an independent replication dataset (Table 2). 
However, none of the associations for these SNPs or additional SNPs in the corresponding 
genes remained statistically significant after controlling for multiple testing (Table 2).
Previous studies have revealed that genetic associations with EOC can differ, sometimes in 
the opposite direction, by histology. Since this effect can mask associations, we performed 
analyses for the four main histological subtypes, separately in the COGs dataset only 
because the discovery set did not have information on all the histological subtypes 
(Supplementary Table 1). This analysis revealed a statistically significant association, after 
controlling for multiple testing, at glypican 6/glypican 5 (GPC6/GPC5) rs17702471 
(OR=1.16, 95%CI=1.07–1.25, p=0.0003, FDR=0.19) for the endometroid subtype among 
Caucasians (Table 3).
Analyses for Asians and African Americans separately in the COGs dataset because the 
discovery set did not have information on these two races. We observed associations at F8 
rs7053448 (OR=1.69, 95%CI=1.27–2.24, p=0.0003, FDR=0.12), F8 rs7058826 (OR=1.69, 
95%CI=1.27–2.24, p=0.0003, FDR=0.12), and CAPN13 rs1983383 (OR=0.79, 
95%CI=0.69–0.90, p=0.0005, FDR=0.12) for combined invasive EOC among Asians (Table 
4). However, F8 rs7053448 and rs7058826 were highly correlated (r2=0.7). No statistical 
significant associations were observed for women of African ancestry.
In silico functional analysis of variants and candidate genes
We used publicly available data, including Haploreg, ENCODE and ovary super-enhancer 
datasets, to test for evidence of functionality of the four SNPs (GPC6/GPC5 rs17702471, F8 
rs7053448, F8 rs7058826 and CAPN13 rs1983383) that were significant after controlling for 
multiple testing. GPC6/GPC5 rs17702471 coincided with functional elements in the datasets 
(Table 5).
Although none of the seven SNPs (NRP2 rs3771044, HEG1/MUC13 rs10460829, GHSP/
TNFSF10 rs2100143, SEMA3C/LOC100128317 rs10954593, SHH rs172310, SEMA4B 
rs8030039 and IGF1R rs10794486) that showed consistent association between the 
discovery and independent replication datasets remained statistically significant after 
multiple testing, we evaluated their functionality because of their consistent associations. 
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Functional analyses indicated a strong evidence of regulatory activity at the NRP2 
rs3771044 polymorphism, which coincided with DNase I hypersensitivity peaks and 
transcription factor binding sites in 62 different cell lines (Hnisz et al, 2013), plus the 
footprint of a super-enhancer (Figure 1), active in ovarian tissue and known to target NRP2. 
NRP2 (neurophilin 2) is a transmembrane glycoprotein that interacts with TGF-β1 signaling 
to promote cancer progression (Grandclement et al. 2011).
DISCUSSION
The current study sought to test the hypothesis that genetic variants in the EMT process 
influence risk of EOC. Seven variants showed nominal consistent associations with EOC in 
the discovery and replication sets among women of European ancestry, but none of them 
reached the threshold for statistical significance after controlling for multiple testing in the 
combined COGS dataset. However, four SNPs showed significant associations, after 
controlling for multiple testing, in the endometrioid subtype among Caucasians (GPC6/
GPC5 rs17702471), and for combined invasive EOC among Asians (F8 rs7053448, F8 
rs7058826 and CAPN13 rs1983383). Rs17702471, an intergenic SNP located between 
GPC5 and GPC6 was associated with the endometroid subtype among women of European-
ancestry. Glypicans (GPC) are a family of heparan sulphate proteoglycans (HSPGs) that are 
attached to the plasma membrane and regulate cell proliferation and division (De Cat and 
David 2001, Filmus and Selleck 2001) and have been previously shown to be involved in 
the development and metastasis of various types of human cancer ((Yang et al. 2013, Zhang 
et al. 2011). Variants in GPC5/GPC6 have been implicated in lung (Li et al. 2010, Liu et al. 
2014), but not ovarian cancer. Rs17702471 coincides with potential regulatory elements and 
further studies evaluating its role in the endometroid histological subtype of ovarian cancer 
are warranted.
F8 rs7053448, F8 rs7058826 and CAPN13 rs1983383 were associated with all invasive 
EOC in Asians. Coagulation factor VIII (F8) participates in the intrinsic pathway of blood 
coagulation. A direct role for F8 has not been established for cancer. Calpain (CAPN) 13 is 
part of a family of cytosolic calcium-activated proteases involved in apoptosis, cell division 
and modulation of integrin-cytoskeletal interaction. Although the associations for these 
SNPs met our threshold for statistical significance, the analyses were exploratory and also 
based on a small sample size. Thus future studies are warranted to confirm these initial 
findings.
Although statistical evidence did not support SNPs that showed consistent nominal 
associations in the discovery and the independent replication datasets, functional data for 
NRP2 rs3771044 may suggest a role in ovarian cancer. This SNP coincides with DNase I 
hypersensitivity peaks and transcription factor binding sites and a super-enhancer active in 
ovarian tissues (Hnisz et al. 2013). Analysis of the expression of NRP2 using TCGA data 
revealed a significantly higher expression in high-grade serous tumors compared to normal 
control tissues (data not shown). Neurophilins are transmembrane glycoproteins that are 
involved in several signaling pathways leading to cytoskeletal organization, angiogenesis 
and cancer progression (Prahst et al. 2008, Soker et al. 2002, Sulpice et al. 2008). A role for 
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NRP2 in ovarian cancer has not been reported previously, thus warranting further evaluation 
of its role in ovarian cancer risk.
Our study is the largest one to date to evaluate EMT-related gene variants in ovarian cancer. 
The study also benefits from other strengths including discovery and replication phases, 
control for population substructure within each ethnicity, biological plausibility of selected 
genes, evaluation of a comprehensive list of SNPs in EMT-related genes, evaluation of 
histological subtypes and race (albeit exploratory) and the tight quality control on the 
genotype data. A limitation of our study is that the analysis in the other ethnic/racial groups 
was based on small numbers and the associations may not be reliable. Future studies with 
larger numbers of African and Asians are therefore warranted.
The results suggest that EMT gene variants do not appear to play a significant role in the 
susceptibility to EOC.
Supplementary Material
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Figure 1. Annotation of regulatory elements at rs3771044
This variant lies within a super-enhancer detected in ovarian tissues (data from Hsinz et al). 
Using data from ENCODE Regulation tracks, we identified evidence of cell type specific 
H3K4me1 marks. This SNP also coincides with ChIPseq marks for multiple transactions 
factors (TFs) including EP300, NFKB and RUNX3. This variant lies with a DNasel 
hypersensitive region detected in 109 samples.
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Table 3
Association between GPC6/GPC5 rs17702471 and histological subtypes of epithelial ovarian cancer among 
Caucasians
Histological subtype P OR(95%CI) FDR
Endometroid 0.00026 1.16 (1.07–1.25) 0.19
Clear Cell 0.013 1.15 (1.03–1.28) 0.80
Mucinous 0.13 1.09 (0.98–1.22) 0.94
Serous 0.21 1.03 (0.98–1.08) 0.77
All invasive 0.019 1.05 (1.01–1.09) 0.55
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